TP53 and neoplasm: Further studies assessing presence of TP53 germline variants, or at least the founder c.1010G>A variant, in Brazilian LUAD patients, regardless of the age at tumor diagnosis and especially if they harbor activating EGFR mutations, should be undertaken in order to determine if universal screening for TP53 c.1010G>A is justified.